“We’re proud of the progress we’ve made this quarter, especially the achievement of the primary endpoint in our COMPANION-002 trial. These positive data reinforce the potential for tovecimig to fill a striking gap in the treatment paradigm for patients with BTC. We expect to share analyses of the secondary endpoints, including progression free survival, overall survival and duration of response, in the fourth quarter of this year,” said Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors. “In parallel, the first patient has been dosed in the IST at The University of Texas MD Anderson Cancer Center evaluating tovecimig in the front-line setting for patients with BTC, and the study continues to actively enroll.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics presents data on efficacy of CTX-471
- Compass Therapeutics’ Tovecimig Shows Promise in BTC Treatment, Supporting Buy Rating
- Compass Therapeutics announces first patient dosed in IST evaluating tovecimig
- Biotech Alert: Searches spiking for these stocks today
- Compass Therapeutics price target raised to $24 from $10 at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue